n Q1 2021, Dutch consumers spent 63 percent more in foreign EU webshops compared to the same quarter last year. Spending stood at nearly 800 million euros, versus around half a billion euros one year previously. Never before has quarterly spending increased so much year-on-year since the implementation of the present measuring method in 2014. Statistics Netherlands (CBS) reports this on the basis of an ongoing survey.
Since 2014, spending by Dutch consumers in foreign EU webshops has been higher in each quarter compared to the same period one year previously. In Q1 2014, Dutch consumers still spent around 150 million euros. This increased fivefold to 778 million euros in Q1 2021, slightly higher than the amount spent in the final quarter of 2020. In recent years prior to this, spending in the first quarter was always lower than in the previous quarter. Especially since the outbreak of the coronavirus crisis in March 2020, spending in EU webshops has risen sharply, probably as a result of the COVID-19 measures. For example, as of 15 December many non-food shops closed their doors and shops were only allowed to have orders collected.
Read more at:
EU webshop sales over 63 percent up in the Netherlands
The Future Is Here Today
Where Business, Nature and Leisure Provide An Ideal Setting For Living
July 26, 2021
July 25, 2021
The Netherlands: Dutch coronavirus average hits two-week low, but Covid hospital total still rising
New data from the RIVM showed that another 4,665 people tested positive for the SARS-CoV-2 coronavirus infection, a figure which has not below five thousand since July 7. That pushed the seven-day moving average down 11 percent in a day to 6,492.
Read more at: Dutch coronavirus average hits two-week low, but Covid hospital total still rising | NL Times
Read more at: Dutch coronavirus average hits two-week low, but Covid hospital total still rising | NL Times
July 24, 2021
COVID-19 vaccine inequity: Inside the cutthroat race to secure doses
No one disputes that the world is unfair. But no one expected a vaccine gap between the global rich and poor that was this bad, this far into the pandemic.
Inequity is everywhere: Inoculations go begging in the United States while Haiti, a short plane ride away, received its first delivery July 15 after months of promises - 500,000 doses for a population over 11 million. Canada has procured more than 10 doses for every resident; Sierra Leone's vaccination rate just cracked 1% on June 20.
It's like a famine in which “the richest guys grab the baker,” said Strive Masiyiwa, the African Union's envoy for vaccine acquisition.
In fact, European and American officials deeply involved in bankrolling and distributing the vaccines against coronavirus have told The Associated Press there was no thought of how to handle the situation globally. Instead, they jostled for their own domestic use.
For the complete detailed report go to: COVID-19 vaccine inequity: Inside the cutthroat race to secure doses | CP24.com
Inequity is everywhere: Inoculations go begging in the United States while Haiti, a short plane ride away, received its first delivery July 15 after months of promises - 500,000 doses for a population over 11 million. Canada has procured more than 10 doses for every resident; Sierra Leone's vaccination rate just cracked 1% on June 20.
It's like a famine in which “the richest guys grab the baker,” said Strive Masiyiwa, the African Union's envoy for vaccine acquisition.
In fact, European and American officials deeply involved in bankrolling and distributing the vaccines against coronavirus have told The Associated Press there was no thought of how to handle the situation globally. Instead, they jostled for their own domestic use.
For the complete detailed report go to: COVID-19 vaccine inequity: Inside the cutthroat race to secure doses | CP24.com
July 23, 2021
Covid-19 not over yet: Surgeon General on Unvaccinated: 'I Am Worried About What Is to Come'
US Surgeon General Vivek Murthy said that he is "worried about what is come" and the COVID-19 "pandemic is not over" amid a surge in cases, particularly among individuals who have yet to get the vaccine.
"I am worried about what is to come because we are seeing increasing cases among the unvaccinated in particular," Murthy said on CNN's "State of the Union" Sunday, the Hill reported. "And while if you are vaccinated you are very well protected against hospitalization and death, unfortunately, that is not true if you are not vaccinated."
Read more at: https://www.businessinsider.com/surgeon-general-on-unvaccinated-i-am-worried-about-what-come-2021-7?international=true&r=US&IR=T
"I am worried about what is to come because we are seeing increasing cases among the unvaccinated in particular," Murthy said on CNN's "State of the Union" Sunday, the Hill reported. "And while if you are vaccinated you are very well protected against hospitalization and death, unfortunately, that is not true if you are not vaccinated."
Read more at: https://www.businessinsider.com/surgeon-general-on-unvaccinated-i-am-worried-about-what-come-2021-7?international=true&r=US&IR=T
July 21, 2021
Covid-19 vaccines: Combatting the crooked global pharmaceutical industry: Fighting Covid-19 requires fewer patents and more state – Piergiuseppe Fortunato
On March 17th 2020, the pharmaceutical giant Pfizer officially partnered with Biopharmaceutical New Technologies (BioNTech), a spinoff of the Johannes Gutenberg-University of Mainz. The partnership was to accelerate a potential first-in-class Covid-19 vaccine (BNT162), using not attenuated or deactivated virus but a strand of messenger ribonucleic acid (mRNA) to produce, and engender immunity against, the virus’ spike protein.
On March 17th 2020, the pharmaceutical giant Pfizer officially partnered with Biopharmaceutical New Technologies (BioNTech), a spinoff of the Johannes Gutenberg-University of Mainz. The partnership was to accelerate a potential first-in-class Covid-19 vaccine (BNT162), using not attenuated or deactivated virus but a strand of messenger ribonucleic acid (mRNA) to produce, and engender immunity against, the virus’ spike protein.
The vaccine was expected to enter clinical testing by the end of the following month. At that point, it had already been almost entirely developed by the small German immunotherapy company. What Pfizer brought to the alliance was essentially funds for the clinical trials and commercial capabilities.
Pfizer, along with the rest of the industry, has been lobbying to stop a temporary waiver of IPR, endorsed by the current US administration under Joe Biden, to allow generic Covid-19 vaccines to be distributed at low cost in the global south. Instead, the industry is asserting monopoly rights in all those developing economies that ratified the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which came into force back in 1995—even at the cost of delaying Covid-19 immunisation worldwide.
Patenting vaccines (and drugs) is particularly problematic, since public research irrigation is preponderant and large companies typically come into play only in the phase of clinical trials, right before patenting, usually when the resources to be invested exceed the financial capacities of small inventors. The pricing of the patented products, however, does not internalise the contribution by other actors, including public institutions, or public-health objectives (such as global immunisation in the case of Covid-19), since the IPR system has not been designed to do so. On the contrary, being subject to intense lobbying and regulatory capture by large companies, the system is often abused and high prices persist, granting to the privileged holders profits not justifiable by their contribution.
This is as socially inequitable as it is economically inefficient—its inadequacy dramatically exposed by the pandemic. Vaccines developed with substantial public contributions are generating hundreds of billions of dollars in sales for the pharmaceutical companies, while the coronavirus is still ravaging poorer nations which cannot afford immunisation.
The vaccine was expected to enter clinical testing by the end of the following month. At that point, it had already been almost entirely developed by the small German immunotherapy company. What Pfizer brought to the alliance was essentially funds for the clinical trials and commercial capabilities.
This is as socially inequitable as it is economically inefficient—its inadequacy dramatically exposed by the pandemic. Vaccines developed with substantial public contributions are generating hundreds of billions of dollars in sales for the pharmaceutical companies, while the coronavirus is still ravaging poorer nations which cannot afford immunisation.
Read the complete report at Fighting Covid-19 requires fewer patents and more state – Piergiuseppe Fortunato
On March 17th 2020, the pharmaceutical giant Pfizer officially partnered with Biopharmaceutical New Technologies (BioNTech), a spinoff of the Johannes Gutenberg-University of Mainz. The partnership was to accelerate a potential first-in-class Covid-19 vaccine (BNT162), using not attenuated or deactivated virus but a strand of messenger ribonucleic acid (mRNA) to produce, and engender immunity against, the virus’ spike protein.
The vaccine was expected to enter clinical testing by the end of the following month. At that point, it had already been almost entirely developed by the small German immunotherapy company. What Pfizer brought to the alliance was essentially funds for the clinical trials and commercial capabilities.
Pfizer, along with the rest of the industry, has been lobbying to stop a temporary waiver of IPR, endorsed by the current US administration under Joe Biden, to allow generic Covid-19 vaccines to be distributed at low cost in the global south. Instead, the industry is asserting monopoly rights in all those developing economies that ratified the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which came into force back in 1995—even at the cost of delaying Covid-19 immunisation worldwide.
Patenting vaccines (and drugs) is particularly problematic, since public research irrigation is preponderant and large companies typically come into play only in the phase of clinical trials, right before patenting, usually when the resources to be invested exceed the financial capacities of small inventors. The pricing of the patented products, however, does not internalise the contribution by other actors, including public institutions, or public-health objectives (such as global immunisation in the case of Covid-19), since the IPR system has not been designed to do so. On the contrary, being subject to intense lobbying and regulatory capture by large companies, the system is often abused and high prices persist, granting to the privileged holders profits not justifiable by their contribution.
This is as socially inequitable as it is economically inefficient—its inadequacy dramatically exposed by the pandemic. Vaccines developed with substantial public contributions are generating hundreds of billions of dollars in sales for the pharmaceutical companies, while the coronavirus is still ravaging poorer nations which cannot afford immunisation.
The vaccine was expected to enter clinical testing by the end of the following month. At that point, it had already been almost entirely developed by the small German immunotherapy company. What Pfizer brought to the alliance was essentially funds for the clinical trials and commercial capabilities.
This is as socially inequitable as it is economically inefficient—its inadequacy dramatically exposed by the pandemic. Vaccines developed with substantial public contributions are generating hundreds of billions of dollars in sales for the pharmaceutical companies, while the coronavirus is still ravaging poorer nations which cannot afford immunisation.
Read the complete report at Fighting Covid-19 requires fewer patents and more state – Piergiuseppe Fortunato
July 19, 2021
The Netherlands : PM Rutte Asks Citizens to Work From Home, Lifting Lockdown an 'Error Of Judgement' - Zoe Strozewski
Dutch Prime Minister Mark Rutte asked citizens to return to working at home as the Netherlands has seen a surge in COVID-19 infection rates, the Associated Press reported. Case numbers rose quickly in the country after the Dutch government loosened lockdown restrictions in June, even permitting nightclubs to reopen.
Read more at: The Netherlands Asks Citizens to Work From Home, Lifting Lockdown an 'Error Of Judgement'
Read more at: The Netherlands Asks Citizens to Work From Home, Lifting Lockdown an 'Error Of Judgement'
July 18, 2021
China - Netherlands relations: China Wants a Chip Machine From the Dutch. The U.S. Said No._ "Is this US Interference in a foreing country's trade policies ?"
Beijing has been pressuring the Dutch government to allow its companies to buy ASML Holding ASML -2.35% NV’s marquee product: a machine called an extreme ultraviolet lithography system that is essential to making advanced microprocessors.
The one-of-a-kind, 180-ton machines are used by companies including Intel Corp. INTC -1.51% , South Korea’s Samsung Electronics Co. and leading Apple Inc. supplier Taiwan Semiconductor Manufacturing Co. to make the chips in everything from cutting-edge smartphones and 5G cellular equipment to computers used for artificial intelligence.
China wants the $150-million machines for domestic chip makers, so smartphone giant Huawei Technologies Co. and other Chinese tech companies can be less reliant on foreign suppliers. But ASML hasn’t sent a single one because the Netherlands—under pressure from the U.S.—is withholding an export license to China.
The Biden administration has asked the government to restrict sales because of national-security concerns, according to U.S. officials. The stance is a holdover from the Trump White House, which first identified the strategic value of the machine and reached out to Dutch officials.
Washington has taken direct aim at Chinese companies like Huawei and has also tried to convince foreign allies to restrict the use of Huawei gear, over spying concerns that Huawei says are unfounded. The pressure aimed at ASML and the Netherlands is different, representing a form of collateral damage in a broader U.S.-China tech Cold War.
Read more at: China Wants a Chip Machine From the Dutch. The U.S. Said No. - WSJ
The one-of-a-kind, 180-ton machines are used by companies including Intel Corp. INTC -1.51% , South Korea’s Samsung Electronics Co. and leading Apple Inc. supplier Taiwan Semiconductor Manufacturing Co. to make the chips in everything from cutting-edge smartphones and 5G cellular equipment to computers used for artificial intelligence.
China wants the $150-million machines for domestic chip makers, so smartphone giant Huawei Technologies Co. and other Chinese tech companies can be less reliant on foreign suppliers. But ASML hasn’t sent a single one because the Netherlands—under pressure from the U.S.—is withholding an export license to China.
The Biden administration has asked the government to restrict sales because of national-security concerns, according to U.S. officials. The stance is a holdover from the Trump White House, which first identified the strategic value of the machine and reached out to Dutch officials.
Washington has taken direct aim at Chinese companies like Huawei and has also tried to convince foreign allies to restrict the use of Huawei gear, over spying concerns that Huawei says are unfounded. The pressure aimed at ASML and the Netherlands is different, representing a form of collateral damage in a broader U.S.-China tech Cold War.
Read more at: China Wants a Chip Machine From the Dutch. The U.S. Said No. - WSJ
Subscribe to:
Posts (Atom)